368 related articles for article (PubMed ID: 14730620)
1. Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma.
Hayakawa I; Hasegawa M; Takehara K; Sato S
Arthritis Rheum; 2004 Jan; 50(1):227-32. PubMed ID: 14730620
[TBL] [Abstract][Full Text] [Related]
2. Anti-DNA topoisomerase II alpha autoantibodies in Japanese patients with systemic sclerosis.
Hayakawa I; Hasegawa M; Takehara K; Sato S
Arch Dermatol Res; 2005 Oct; 297(4):180-3. PubMed ID: 16180014
[TBL] [Abstract][Full Text] [Related]
3. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis.
Hénault J; Tremblay M; Clément I; Raymond Y; Senécal JL
Arthritis Rheum; 2004 Oct; 50(10):3265-74. PubMed ID: 15476238
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies against matrix metalloproteinase-1 in patients with localized scleroderma.
Tomimura S; Ogawa F; Iwata Y; Komura K; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
J Dermatol Sci; 2008 Oct; 52(1):47-54. PubMed ID: 18565735
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and characteristics of anti-single-stranded DNA antibodies in localized scleroderma. Comparison with systemic lupus erythematosus.
Ruffatti A; Peserico A; Rondinone R; Calligaro A; Del Ross T; Ghirardello A; Germino M; Todesco S
Arch Dermatol; 1991 Aug; 127(8):1180-3. PubMed ID: 1863075
[TBL] [Abstract][Full Text] [Related]
6. Anti-agalactosyl immunoglobulin G antibodies in localized scleroderma.
Mimra Y; Ihn H; Jinnin M; Asano Y; Yamane K; Yazawa N; Tamaki K
Int J Dermatol; 2005 Oct; 44(10):817-20. PubMed ID: 16207181
[TBL] [Abstract][Full Text] [Related]
7. Antinucleosome antibody is a major autoantibody in localized scleroderma.
Sato S; Kodera M; Hasegawa M; Fujimoto M; Takehara K
Br J Dermatol; 2004 Dec; 151(6):1182-8. PubMed ID: 15606513
[TBL] [Abstract][Full Text] [Related]
8. Antinuclear antibodies in children with localized scleroderma.
Rosenberg AM; Uziel Y; Krafchik BR; Hauta SA; Prokopchuk PA; Silverman ED; Laxer RM
J Rheumatol; 1995 Dec; 22(12):2337-43. PubMed ID: 8835572
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies against calpastatin in sera from patients with systemic sclerosis.
Sato S; Hasegawa M; Nagaoka T; Takamatsu Y; Yazawa N; Ihn H; Kikuchi K; Takehara K
J Rheumatol; 1998 Nov; 25(11):2135-9. PubMed ID: 9818655
[TBL] [Abstract][Full Text] [Related]
10. Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations.
Kodera M; Hayakawa I; Komura K; Yanaba K; Hasegawa M; Takehara K; Sato S
J Rheumatol; 2005 Apr; 32(4):629-36. PubMed ID: 15801017
[TBL] [Abstract][Full Text] [Related]
11. An immunodominant epitope on DNA topoisomerase I is conformational in nature: heterogeneity in its recognition by systemic sclerosis sera.
Kuwana M; Kaburaki J; Medsger TA; Wright TM
Arthritis Rheum; 1999 Jun; 42(6):1179-88. PubMed ID: 10366110
[TBL] [Abstract][Full Text] [Related]
12. Expression of cell proliferation markers in pituitary adenomas--correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha.
Wolfsberger S; Wunderer J; Zachenhofer I; Czech T; Böcher-Schwarz HG; Hainfellner J; Knosp E
Acta Neurochir (Wien); 2004 Aug; 146(8):831-9. PubMed ID: 15254805
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients.
Hénault J; Robitaille G; Senécal JL; Raymond Y
Arthritis Rheum; 2006 Mar; 54(3):963-73. PubMed ID: 16508979
[TBL] [Abstract][Full Text] [Related]
14. Autoantibody against peroxiredoxin I, an antioxidant enzyme, in patients with systemic sclerosis: possible association with oxidative stress.
Iwata Y; Ogawa F; Komura K; Muroi E; Hara T; Shimizu K; Hasegawa M; Fujimoto M; Tomita Y; Sato S
Rheumatology (Oxford); 2007 May; 46(5):790-5. PubMed ID: 17309887
[TBL] [Abstract][Full Text] [Related]
15. Anti-p53 autoantibody in systemic sclerosis: association with limited cutaneous systemic sclerosis.
Hara T; Ogawa F; Muroi E; Komura K; Takenaka M; Hasegawa M; Fujimoto M; Sato S
J Rheumatol; 2008 Mar; 35(3):451-7. PubMed ID: 18203319
[TBL] [Abstract][Full Text] [Related]
16. Antigen specificity of antihistone antibodies in localized scleroderma.
Sato S; Fujimoto M; Ihn H; Kikuchi K; Takehara K
Arch Dermatol; 1994 Oct; 130(10):1273-7. PubMed ID: 7524451
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of soluble interleukin 6 receptor and soluble gp130 are elevated in patients with localized scleroderma.
Nagaoka T; Sato S; Hasegawa M; Ihn H; Takehara K
J Rheumatol; 2000 Aug; 27(8):1917-21. PubMed ID: 10955333
[TBL] [Abstract][Full Text] [Related]
18. Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease.
Ihn H; Yazawa N; Kubo M; Yamane K; Sato S; Fujimoto M; Kikuchi K; Soma Y; Tamaki K
J Rheumatol; 2000 Mar; 27(3):698-702. PubMed ID: 10743811
[TBL] [Abstract][Full Text] [Related]
19. T and B cell collaboration is essential for the autoantibody response to DNA topoisomerase I in systemic sclerosis.
Kuwana M; Medsger TA; Wright TM
J Immunol; 1995 Sep; 155(5):2703-14. PubMed ID: 7650398
[TBL] [Abstract][Full Text] [Related]
20. Diversity and plasticity of the anti-DNA topoisomerase I autoantibody response in scleroderma.
Henry PA; Atamas SP; Yurovsky VV; Luzina I; Wigley FM; White B
Arthritis Rheum; 2000 Dec; 43(12):2733-42. PubMed ID: 11145031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
